Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/28730
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMAGALHÃES, Silvia Maria Meira
dc.contributor.authorCHAUFFAILLE, Maria de Lourdes Lopes Ferrari
dc.contributor.authorVELLOSO, Elvira Deolinda Rodrigues Pereira
dc.contributor.authorBUZZINI, Renata
dc.contributor.authorBERNARDO, Wanderley Marques
dc.date.accessioned2018-10-11T19:03:48Z
dc.date.available2018-10-11T19:03:48Z
dc.date.issued2018
dc.identifier.citationHEMATOLOGY, TRANSFUSION AND CELL THERAPY, v.40, n.3, p.278-282, 2018
dc.identifier.issn2531-1379
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/28730
dc.language.isoeng
dc.publisherAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
dc.relation.ispartofHematology, Transfusion and Cell Therapy
dc.rightsopenAccess
dc.titlePart 5: Myelodysplastic syndromes—Treatment of high-risk disease
dc.typearticle
dc.rights.holderCopyright Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
dc.identifier.doi10.1016/j.htct.2018.05.013
dc.identifier.pmid30128439
dc.subject.wosMedicine, General & Internal
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
hcfmusp.author.externalMAGALHÃES, Silvia Maria Meira:Universidade Federal do Ceará, Brazil
hcfmusp.author.externalCHAUFFAILLE, Maria de Lourdes Lopes Ferrari:Grupo Fleury, Brazil; Universidade Federal de São Paulo, Brazil
hcfmusp.author.externalBUZZINI, Renata:Associação Médica Brasileira, Brazil
hcfmusp.description.beginpage278
hcfmusp.description.endpage282
hcfmusp.description.issue3
hcfmusp.description.volume40
hcfmusp.origemWOS
hcfmusp.origem.idSCIELO:S2531-13792018000300278
hcfmusp.origem.id2-s2.0-85050809031
hcfmusp.origem.idWOS:000587465200015
hcfmusp.relation.referenceCheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149
hcfmusp.relation.referencede Witte T, 2017, BLOOD, V129, P1753, DOI [10.1182/blood-2016-06724500, 10.1182/blood-2016-06-724500]
hcfmusp.relation.referencede Witte T, 2010, HAEMATOL-HEMATOL J, V95, P1754, DOI 10.3324/haematol.2009.019182
hcfmusp.relation.referenceDella Porta MG, 2017, LEUKEMIA, V31, P2449, DOI 10.1038/leu.2017.88
hcfmusp.relation.referenceDenzlinger C, 2000, BRIT J HAEMATOL, V108, P93
hcfmusp.relation.referenceFenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
hcfmusp.relation.referenceFerrara F, 1999, CANCER, V86, P2006, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2006::AID-CNCR18>3.0.CO;2-2
hcfmusp.relation.referenceGoldet Gabrielle, 2013, J Evid Based Med, V6, P50, DOI 10.1111/jebm.12018
hcfmusp.relation.referenceItzykson R, 2011, BLOOD, V117, P403, DOI 10.1182/blood-2010-06-289280
hcfmusp.relation.referenceKantarjian H, 2006, CANCER, V106, P1794, DOI 10.1002/cncr.21792
hcfmusp.relation.referenceKantarjian H, 2006, CANCER, V106, P1099, DOI 10.1002/cncr.21699
hcfmusp.relation.referenceKantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162
hcfmusp.relation.referenceKantarjian HM, 2007, CANCER-AM CANCER SOC, V109, P1133, DOI 10.1002/cncr.22508
hcfmusp.relation.referenceKroger N, 2017, J CLIN ONCOL, V35, P2157, DOI 10.1200/JCO.2016.70.7349
hcfmusp.relation.referenceLubbert M, 2011, J CLIN ONCOL, V29, P1987, DOI 10.1200/JCO.2010.30.9245
hcfmusp.relation.referenceMILLER KB, 1992, ANN HEMATOL, V65, P162, DOI 10.1007/BF01703109
hcfmusp.relation.referenceOki Y, 2012, CANCER SCI, V103, P1839, DOI 10.1111/j.1349-7006.2012.02386.x
hcfmusp.relation.referenceOmoto E, 1996, LEUKEMIA, V10, P609
hcfmusp.relation.referenceScott BL, 2017, J CLIN ONCOL, V35, P1154, DOI 10.1200/JCO.2016.70.7091
hcfmusp.relation.referenceShaffer BC, 2016, J CLIN ONCOL, V34, P1864, DOI 10.1200/JCO.2015.65.0515
hcfmusp.relation.referenceSilverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117
hcfmusp.relation.referenceXie MX, 2015, CL LYMPH MYELOM LEUK, V15, P22, DOI 10.1016/j.clml.2014.04.010
hcfmusp.relation.referenceZhao WH, 2015, LEUKEMIA RES, V39, P424, DOI 10.1016/j.leukres.2015.01.014
hcfmusp.relation.referenceLevels of Evidence and Grades of Recommendations, Oxford Centre for Evidence Based Medicine
dc.description.indexWoS
hcfmusp.citation.scopus0
hcfmusp.scopus.lastupdate2022-06-17-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM


Files in This Item:
File Description SizeFormat 
art_MAGALHÃES_Part_5_Myelodysplastic_syndromes—Treatment_of_highrisk_disease_2018.PDFpublishedVersion (English)288.02 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.